Searching for Joy (and Value) in SPACville

Three baseball-related SPACs have attractive potential, but when will they reward investors?

Jim Cramer: An Intel/GlobalFoundries Deal Likely Isn't Going Anywhere

It's the type of transition the Biden team probably would put its antitrust lawyers on to squelch, again leaving Intel with no quick fix.

Does the Latest SPAC Mess Spell Disaster or Opportunity in the Sector?

Here's my answer to a tough question.

2 Small Stocks to Watch as Conditions Ripen for Biotech Merger Deals

Ardelyx Inc. and Rigel Pharmaceuticals look good as stand-alone companies but also could attract suitors.

Earnings Await, Fed Heads Ahead, the Materials World, Microsoft's Cyber Pickup

Plus, the chart of Tesla indicates it's time to be wary if you're in the stock at present.

CNH Industrial Looks Ready to Emerge From a Decades-Long Basing Pattern

However, shares of the maker of agricultural and construction equipment still could see a period of sideways price action for a while.

Seven Oaks Acquisition's Brief History Suggests It Has Formed a Base

Shares of the SPAC that soon will be the vehicle to take e-commerce grocery platform Boxed public have firmed of late.

Move Fast to Hop on American Financial's Whopper of a Special Dividend

The insurer's recent sale of a chunk of its business has led the company to share in the proceeds with its shareholders.

Tootsie Roll Shows the Downside of a Family-Controlled Publicly Traded Firm

I still believe TR would command a solid premium in an acquisition, but I'm not holding my breath.

Enveric Envisions Using Mushrooms and Cannabis to Help Patients

The cannabis biotech company explains why the acquisition of MagicMed makes sense, additional capital raises and the Psybrary.